Home >
AEPSO Argentina launches digital map to find people with psoriasis in the country
2015/04/09 - News from patients associations
Psoriasis, recognised today by the World Health Organization (WHO) as a painful and incapacitating non communicable chronic disease, affects more than 800 000 Argentineans. AEPSO (Asociación Civil para el Enfermo de Psoriasis) celebrates its 10th anniversary raising awareness and supporting the rights of the patients. In order to better know what is going on with the disease in Argentina and to reach out the different communities, AEPSO has launched an interactive digital map, accessible through Facebook, that aims to identify and connect all psoriasis patients in each corner of the country.
Silvia Fernández Barrio, president and founder of AEPSO, has acknowledged that social networks have contributed to show unknown realities that they wish to work on for the benefit of the patients: “This is why this map came about, a tool that will give precise information where persons with psoriasis in Argentina live, and thus better help each one of them, guide them to informed professionals and to centres where they can get the treatment they need, as well as to create ties among patients going through the same experience in their community. In a territory as vast and with different realities we have to take advantage of technology as an opportunity to shorten distance and time”.
During the next 10 years, Beatriz Larrea, Executive Director of AEPSO, said that “we would like to achieve a presence of groups of people with psoriasis in every region of the country. That there are patients gathering, giving their time and sharing their experiences and knowledge in order to help others to better cope with their reality”.
One of the greatest obstacles that a psoriasis patients still faces is ignorance. There are patients that do not see a doctor because of the old prejudice that this is a disease that there is nothing you can do, so they give up. “Nothing could be farther from the truth”, exclaimed Silvia Fernández Barrio, adding “those people we must reach them through AEPSO; so that they know who we are, that we are here to help them, guide them, provide them with information and suggest where they can start to treat themselves. Their life can change, and is going to change”.
“We strive to achieve that no patient across the country lives withouth diagnosis or treatment; we have a lot of work ahead of us, but we know this is the way”, added the president of AEPSO.
You can find the map at:
https://www.facebook.com/pages/AEPSO/103448854973?sk=app_1497274527196166
SPIN Presentation
Recent news
- 2019/05/21 Focus on...
- 2019/04/18 Focus on...
- 2019/04/17 Focus on...
- 2018/07/16 Focus on...
- 2018/07/09 Focus on...
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
IL-33 contributes to disease severity in Psoriasis-like models of mouse.
Duan Y et al.
IL-33 contributes to disease severity in Psoriasis-like models of mouse.
Cytokine.
2019 Jul , 119:159-167.
Immune cells infiltrating the psoriatic skin secrete high amounts of pro-inflammatory cytokines IL-17, TNF-α, IL-21 and IL-36 resulting in chronic inflammation. However, the exact cellular and molecular mechanisms have not been fully understood. We report here elevation of IL-33 expression in psoriatic lesions. Studies in imiquimod (IMQ)-induced mice with psoriatic inflammation confirmed a critical role for IL-33 in driving the disease. IL-33 reduces the CD4 and CD8 cells, inhibits autophagy (...)
see on pubmed
Association of plasma and urine metals levels with kidney function: A population-based cross-sectional study in China.
Chemosphere.
2019 Jul , 226:321-328.
Although environmental exposure to multiple metals is common, epidemiological studies on the associations of exposure to 23 metals with kidney function have not been analyzed. We aimed to investigate the associations of 23 metals levels with renal function.
see on pubmed
Models of human psoriasis: Zebrafish the newly appointed player.
Martínez-Navarro FJ et al.
Models of human psoriasis: Zebrafish the newly appointed player.
Dev. Comp. Immunol..
2019 Aug , 97:76-87.
Psoriasis is a human chronic, immune disease with severe cutaneous and systemic manifestations. Its prevalence, among the world population, highly varies with ethnicity and geography, but not sex from remarkable low levels in Asia to 2.3% in Spain, or an impressive 11.5% in Norway. The pathogenesis of psoriasis derives from complex genetic and environmental interactions, which creates aberrant crosstalk between keratinocytes and variated immune cell, resulting in open amplified inflammatory (...)
see on pubmed
on Atopic Dermatitis
What's new in atopic eczema? An analysis of systematic reviews published in 2016. Part 3: nomenclature and outcome assessment.
Clin. Exp. Dermatol..
2019 Jun , 44, (4):376-380.
This review forms part of a series of annual updates that summarize the evidence base for atopic eczema (AE). It presents the key findings from 11 systematic reviews published in 2016 that focus on AE outcome assessment, disease impact and nomenclature. Systematic reviews on the treatment and prevention of AE are summarized in Part 1 of this update, and systematic reviews on the epidemiology of and risk factors for AE are summarized in Part 2. Six reviews summarized what outcome measurement (...)
see on pubmed
Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling.
Bioorg. Med. Chem. Lett..
2019 Jun 15, 29, (12):1522-1531.
Disruption of interleukin-13 (IL-13) signaling with large molecule antibody therapies has shown promise in diseases of allergic inflammation. Given that IL-13 recruits several members of the Janus Kinase family (JAK1, JAK2, and TYK2) to its receptor complex, JAK inhibition may offer an alternate small molecule approach to disrupting IL-13 signaling. Herein we demonstrate that JAK1 is likely the isoform most important to IL-13 signaling. Structure-based design was then used to improve the (...)
see on pubmed
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
Choi EJ et al.
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
J Enzyme Inhib Med Chem.
2019 Dec , 34, (1):613-619.
This study aimed to evaluate the effects of cinnamamides on atopic dermatitis (AD) and the mechanisms underlying these effects. To this end, the actions of two cinnamamides, (E)-3-(4-hydroxyphenyl)-N-phenylethyl acrylamide (NCT) and N-trans-coumaroyltyramine (NCPA), were determined on AD by orally administering them to mice. Oral administration of the cinnamamides ameliorated the increase in epidermal and dermal thickness as well as mast cell infiltration. Cinnamamides suppressed serum (...)
see on pubmed
